What are the next steps if Hemolytic Uremic Syndrome (HUS) is suspected?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Workup When HUS is Suspected

If you suspect HUS, immediately order haptoglobin, indirect bilirubin, LDH, complete blood count with peripheral smear, ADAMTS13 activity, and stool testing for verocytotoxin-producing E. coli (VTEC) while initiating urgent hematology consultation. 1, 2

Immediate Laboratory Testing

First-Level Essential Tests

When anemia plus thrombocytopenia presents in the emergency setting, you must immediately obtain: 1

  • Haptoglobin (will be reduced in hemolysis) 1
  • LDH (will be elevated) 1
  • Indirect bilirubin (will be elevated) 1
  • Complete blood count with peripheral blood smear looking for schistocytes >1% 1, 2
  • Direct Coombs test (must be negative to confirm non-immune hemolysis) 1
  • Creatinine (assess renal involvement, interpret relative to age in children) 2
  • Urinalysis (check for hematuria and/or proteinuria) 1

Critical Differential Diagnosis Tests

Order ADAMTS13 activity urgently before initiating any plasma therapy to distinguish thrombotic thrombocytopenic purpura (TTP) from HUS—severely deficient activity <10 IU/dL indicates TTP rather than HUS. 1, 2

Obtain stool testing for VTEC/Shiga toxin to differentiate typical (STEC-HUS) from atypical HUS (aHUS). 1, 2

Key Diagnostic Pitfalls to Avoid

Do Not Exclude HUS Based on:

  • Absence of schistocytes: The test has low sensitivity, and their absence should not exclude early TMA diagnosis 1, 2, 3
  • Absence of marked thrombocytopenia or anemia: Particularly in post-transplant patients, 13% do not show significant platelet reduction and 38% lack significant anemia or thrombocytopenia 1
  • Missing one parameter in children: In pediatric patients, especially newborns, HUS may be present even if one of the three main parameters (thrombocytopenia, anemia, or elevated creatinine) is absent 2, 3
  • Normal platelet count if obtained >7 days after symptom onset: Platelets may normalize or increase later in the illness 3

Distinguishing STEC-HUS from Atypical HUS

Timing of Diarrhea is Critical:

  • STEC-HUS typically appears 4-5 days after diarrhea onset 1
  • Suspect aHUS if: Short period of diarrhea OR simultaneous appearance of diarrhea and HUS symptoms 1, 3
  • Typical HUS: Onset within 3 weeks after acute or bloody diarrhea 3

Additional Workup for Suspected Atypical HUS

Second-Level Testing:

  • Complement testing: C3, C4, CH50, AP50 2
  • Genetic screening for complement pathway mutations (though do NOT delay treatment waiting for results) 2, 4

Special Populations:

In children <1 year old: Consider mutations in complement-unrelated genes (DGKE, WT1) and inborn errors of cobalamin metabolism (MMACHC) 1, 5

In post-transplant patients: Maintain high suspicion even without typical laboratory findings, as diagnosis is particularly challenging in this population 1

Neurological Assessment

If neurological symptoms are present (occurs in 10-20% of aHUS cases), obtain: 1, 5

  • Neurological consultation 1, 5
  • Electroencephalogram (EEG) 1, 5
  • Brain MRI looking for bilateral symmetrical hyperintensities of basal ganglia on FLAIR and T2-weighted sequences, which are suggestive of TMA 1

Common neurological manifestations include motor symptoms, generalized weakness, vision changes, seizures, and encephalopathy. 1

Concurrent Management While Awaiting Results

Do not delay initiating complement inhibitor therapy (eculizumab/ravulizumab) while awaiting genetic testing results, as genetic mutations are found in only 50-60% of aHUS cases and the disease carries high morbidity and mortality when untreated. 2, 4

Avoid: 2, 6

  • Platelet transfusions (unless life-threatening bleeding, as they may worsen TMA) 2
  • Antidiarrheal drugs 6
  • Antibiotics in suspected STEC-HUS (controversial) 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnosis and Treatment of Hemolytic Uremic Syndrome (HUS)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnostic Criteria and Considerations for Hemolytic Uremic Syndrome (HUS)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.

Clinical advances in hematology & oncology : H&O, 2016

Guideline

Diagnóstico y Tratamiento del Síndrome Hemolítico Urémico Atípico

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Haemolytic uraemic syndrome: an overview.

Nephrology (Carlton, Vic.), 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.